Who Optimizes SG&A Costs Better? Genmab A/S or Geron Corporation

Optimizing SG&A: A Tale of Two Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Genmab A/S and Geron Corporation, two prominent players, showcase contrasting strategies over the past decade.

Genmab A/S: A Steep Climb

From 2014 to 2023, Genmab A/S saw a staggering 4,000% increase in SG&A expenses, reflecting its aggressive expansion and investment in growth. By 2023, their expenses reached a peak, indicating a robust strategy to capture market share.

Geron Corporation: Steady and Strategic

In contrast, Geron Corporation maintained a more conservative approach, with SG&A expenses growing by approximately 300% over the same period. This steady increase suggests a focus on sustainable growth and cost efficiency.

Conclusion

While Genmab A/S's rapid increase in SG&A expenses highlights its ambitious growth strategy, Geron Corporation's steady rise underscores a more cautious, yet potentially more sustainable, approach.